

学会活動（井手広樹）

2018年10月 日本癌治療学会 (優秀演題賞) 酸性尿による経尿道的膀胱腫瘍切除後の上部尿路発癌発生リスクの上昇

2018年5月 アメリカ泌尿器科学会

•ANDROGEN RECEPTOR SIGNALING REDUCES RADIOSENSITIVITY IN BLADDER CANCER

•GLUCOCORTICOID RECEPTOR AND FOXO1 EXPRESSION IN BLADDER CANCER AS AN INDEPENDENT PROGNOSTICATOR

2017年5月 アメリカ泌尿器科学会

NUCLEAR FACTOR (NF)- κ B SIGNALS PROMOTE UROTHELIAL TUMORIGENESIS THROUGH THE ANDROGEN RECEPTOR (AR) PATHWAY

ANDROGEN RECEPTOR ACTIVITY MODULATES RADIOSENSITIVITY IN BLADDER CANCER CELLS

ESTROGEN RECEPTOR (ER)- β SIGNALS INDUCE UROTHELIAL TUMORIGENESIS VIA DOWN-REGULATION OF A POTENTIAL TUMOR SUPPRESSOR FORKHEAD BOX PROTEIN O1 (FOXO1)

Loss of forkhead box protein O1 in bladder cancer promotes progression and cisplatin resistance.

2017年4月 日本泌尿器科学会総会 泌尿器癌基礎研究の今後

2016年5月 アメリカ泌尿器科学会

ROLE OF GLUCOCORTICOID RECEPTOR (GR) SIGNALING IN UROTHELIAL TUMORIGENESIS: INHIBITION BY COMPOUND A (CPDA) VIA BOTH GR AND ANDROGEN RECEPTOR (AR) PATHWAYS

FOXO1 AS A POTENTIAL TUMOR SUPPRESSOR IS INACTIVATED BY ANDROGENS IN BLADDER CANCER CELLS

2015年5月 アメリカ泌尿器科学会

Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.

URINARY PH IS HIGHLY ASSOCIATED WITH BLADDER RECURRENCE AFTER NEPHROURETERECTOMY FOR UPPER URINARY TRACT UROTHELIAL CARCINOMA PATIENTS WITH POSITIVE SMOKING HISTORY

学会活動（丹羽先生）

2018年 4月 日本泌尿器科学会総会（総会賞受賞） 丹羽直也 The clinical role of purified protein derivative skintest in patients with non-muscle invasive bladder cancer treated with adjuvant BCG.

2018年 5月 アメリカ泌尿器科学会

- MP08-04 - Purified protein derivative skin test prior to bacillus Calmette-Guérin therapy enhances the clinical efficacy of BCG therapy in patients with non-muscle invasive bladder cancer
- MP08-11 - Switching of bacillus Calmette-Guérin (BCG) strain at second BCG therapy may reduce BCG-related side effects in patients with BCG-relapsing tumor.
- PD66-02 THE CLINICAL IMPACT OF INDURATION RESULTING FROM PURIFIED PROTEIN DEPRIVATION SKIN TEST IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS-CALMETTE GUÉRIN

2017年 5月 アメリカ泌尿器科学会

PD48-09 PURIFIED PROTEIN DEPRIVATION SKIN TEST REACTION IS ASSOCIATED WITH CLINICAL OUTCOME OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS-CALMETTE GUERIN

2016年 5月 アメリカ泌尿器科学会

MP27-05 ARE CALCULATED FORMULAS FOR ESTIMATING RENAL FUNCTION ADEQUATE FOR ADMINISTERED CISPLATIN-BASED CHEMOTHERAPY IN SOLITARY RENAL PATIENTS AFTER NEPHROURETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA?

MP54-04 SIMPLE AND PRACTICAL NOMOGRAMS FOR PREDICTING STONE-FREE RATE AFTER EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY IN PATIENTS WITH SOLITARY STONE IN UPPER URINARY TRACT

PD11-12 COMPARISON OF OUTCOMES BETWEEN ULTRASONOGRAPHY AND CYSTOSCOPY IN THE SURVEILLANCE OF PATIENTS WITH LOW- OR INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER

2018 年	Author	Journal	Volume	Number	Start	End
Forkhead box O1 as an indicator of prognosis is inactivated in urothelial carcinoma of the upper urinary tract.	Ide H, Jiang G, Mizushima T, Fujita K, Inoue S, Yamaguchi S, Fushimi H, Nonomura N, Miyamoto H.	Oncol Lett	17	1	482	487
ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling.	Inoue S, Mizushima T, Ide H, Jiang G, Goto T, Nagata Y, Netto GJ, Miyamoto H.	Endocr Connect	7	12	1397	1408
The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression.	Ide H, Inoue S, Miyamoto H.	Cancers (Basel)	10	12		
ELK1 promotes urothelial tumorigenesis in the presence of an activated androgen receptor.	Inoue S, Ide H, Mizushima T, Jiang G, Kawahara T, Miyamoto H.	Am J Cancer Res	8	11	2325	2336
Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer.	Ide H, Inoue S, Mizushima T, Jiang G, Chuang KH, Oya M, Miyamoto H.	Mol Cancer Ther	17	7	1566	1574
Nuclear Factor- κ B Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling.	Inoue S, Ide H, Mizushima T, Jiang G, Netto GJ, Gotoh M, Miyamoto H.	Mol Cancer Ther.	17	6	1303	1314
Uridine 5'diphospho-glucuronosyltransferase 1A expression as an independent prognosticator in urothelial carcinoma of the upper urinary tract.	Izumi K, Inoue S, Ide H, Fujita K, Mizushima T, Jiang G, Yamaguchi S, Fushimi H, Nonomura N, Miyamoto H.	Int J Urol.	25	5	429	435
The interaction between androgen receptor and semenogelin I: a	Li P, Chen J, Kashiwagi E, Mizushima T, Han B, Inoue S, Ide H, Izumi K, Miyamoto	Br J Cancer.	118	3	416	420

synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells.	H.						
Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.	Kashiwagi E, Inoue S, Mizushima T, Chen J, Ide H, Kawahara T, Reis LO, Baras AS, Netto GJ, Miyamoto H.	Br J Cancer.	118	2	213	223	
2017 年							
Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesis.	Kawahara T, Inoue S, Kashiwagi E, Chen J, Ide H, Mizushima T, Li Y, Zheng Y, Miyamoto H.	Am J Cancer Res	7	10	2041	2050	
NFATc1 Expression as a Prognosticator in Urothelial Carcinoma of the Upper Urinary Tract.	Kawahara T, Inoue S, Fujita K, Mizushima T, Ide H, Yamaguchi S, Fushimi H, Nonomura N, Miyamoto H.	Transl Oncol.	10	3	318	323	
GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.	Inoue S, Mizushima T, Fujita K, Meliti A, Ide H, Yamaguchi S, Fushimi H, Netto GJ, Nonomura N, Miyamoto H.	Hum Pathol.	64		83	90	
Histopathological and prognostic significance of the expression of sex hormone receptors in bladder cancer: A meta-analysis of immunohistochemical studies.	Ide H, Inoue S, Miyamoto H.	PLoS One	12(3)	e0174746			
2016 年							
Urinary pH Levels are Strongly Associated with Bladder Recurrence After Nephroureterectomy in Upper Tract Urothelial Carcinoma Patients	Ide H, Kikuchi E, Hagiwara M, Hayakawa N, Hongo H, Miyajima A, Oya M	Ann Surg Oncol.	23	Suppl 5	1029	1038	

with a Smoking History.

Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract.	Kashiwagi E, Fujita K, Yamaguchi S, Fushimi H, Ide H, Inoue S, Mizushima T, Reis LO, Sharma R, Netto GJ, Nonomura N, Miyamoto H.	Cancer Biol Ther.	17	11	1188	1196
Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.	Kawahara T, Ide H, Kashiwagi E, El-Shishtawy KA, Li Y, Reis LO, Zheng Y, Miyamoto H.	Urol Oncol	34(10)	432	e15	e23
ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion.	Kawahara T, Inoue S, Ide H, Kashiwagi E, Ohtake S, Mizushima T, Li P, Li Y, Zheng Y, Uemura H, Netto GJ, Ishiguro H, Miyamoto H.	Oncotarget.	7	33	53599	53610
Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.	Kashiwagi E, Ide H, Inoue S, Kawahara T, Zheng Y, Reis LO, Baras AS, Miyamoto H.	Oncotarget.	7	31	49169	49179
Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.	Kawahara T, Aljarah AK, Shareef HK, Inoue S, Ide H, Patterson JD, Kashiwagi E, Han B, Li Y, Zheng Y, Miyamoto H.	Prostate	76	8	744	756
Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy.	Kobayashi H, Kikuchi E, Tanaka N, Shirotake S, Miyazaki Y, Ide H, Obata J, Hoshino K, Matsumoto K, Kaneko G, Hagiwara M, Kosaka T, Oyama M, Nakajima Y, Oya M.	Jpn J Clin Oncol.	46	6	554	559
2015 年						
Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.	Zheng Y, Ishiguro H, Ide H, Inoue S, Kashiwagi E, Kawahara T, Jalalizadeh M, Reis LO, Miyamoto H.	Mol Endocrinol.	29	10	1486	1497

ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.	Kawahara T, Shareef HK, Aljarah AK, Ide H, Li Y, Kashiwagi E, Netto GJ, Zheng Y, Miyamoto H.	Oncotarget.	6	30	29860	29876
Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.	Kawahara T, Ide H, Kashiwagi E, Patterson JD, Inoue S, Shareef HK, Aljarah AK, Zheng Y, Baras AS, Miyamoto H.		5	10	2959	2968
Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis.	Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Nakagawa K, Jinzaki M, Oya M.	Eur Urol Focus	1	1	54	63
The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.	Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Ishiguro H, Miyamoto H.	Prostate	75	6	573	584
Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.	Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M.	J Urol.	193	4	1122	1128
Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1.	Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H, Miyamoto H.	Oncotarget.	6	3	1582	1593
Steroid Hormone Receptor Signals as	Ide H, Miyamoto H	Dis Markers			840640	

Prognosticators for Urothelial Tumor.

2018年

[The clinical implication of gamma globulin levels in patients with nonmuscle-invasive bladder cancer.](#)

Niwa N, Matsumoto K, Ide H.

Urol Oncol. 2019 Apr;37(4):291.e1-291.e7.

[Immunoglobulin G4-Related Disease Arising from the Bladder Wall.](#)

Kufukihara R, **Niwa N**, Mizuno R, Ohara K, Mikami S, Kikuchi E, Oya M.

Urol Int. 2018 Dec 13:1-3. doi: 10.1159/000495570. [Epub ahead of print]

PMID:

[Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63.](#)

Tanaka N, Katayama S, Reddy A, Nishimura K, **Niwa N**, Hongo H, Ogihara K, Kosaka T, Mizuno R, Kikuchi E, Mikami S, Miyakawa A, Arenas E, Kere J, Oya M, Uhlén P.

Cancer Med. 2018 Dec;7(12):6193-6204. doi: 10.1002/cam4.1828. Epub 2018 Oct 26.

[Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy.](#)

Niwa N, Matsumoto K, Nishiyama T, Yagi Y, Ozu C, Nakamura K, Saito S, Oya M.

Brachytherapy. 2018 Nov - Dec;17(6):899-905. doi: 10.1016/j.brachy.2018.08.018. Epub 2018 Sep 21.

[Establishment of the optimal follow-up schedule after radical prostatectomy.](#)

Matsumoto K, **Niwa N**, Hattori S, Takeda T, Morita S, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Asanuma H, Oya M.

Urol Oncol. 2018 Jul;36(7):341.e9-341.e14. doi: 10.1016/j.urolonc.2018.04.003. Epub 2018 May 3.

[Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Guérin Therapy.](#)

Fukumoto K, Kikuchi E, Mikami S, Hayakawa N, Matsumoto K, **Niwa N**, Oya M.

Ann Surg Oncol. 2018 Aug;25(8):2484-2491. doi: 10.1245/s10434-018-6498-2. Epub 2018 May 1.

[Incidence and timing of inadvertent nephrostomy catheter displacement in patients with ureteral obstruction .](#)

Niwa N, Matsumoto K, Kikuchi E, Yazawa S, Takeda T, Morita S, Kosaka T, Shinoda K, Mizuno R, Shinojima T, Asanuma H, Oya M.

Clin Nephrol. 2018 Aug;90(2):112-116. doi: 10.5414/CN109294.

[Does switching the bacillus Calmette-Guérin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?](#)

Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M.

Urol Oncol. 2018 Jun;36(6):306.e1-306.e8. doi: 10.1016/j.urolonc.2018.02.005. Epub 2018 Mar 9.

[Prognostic Value of Pretreatment Albumin-to-Globulin Ratio in Patients With Non-Muscle-Invasive Bladder Cancer.](#)

Niwa N, Matsumoto K, Ide H, Nagata H, Oya M.

Clin Genitourin Cancer. 2018 Jun;16(3):e655-e661. doi: 10.1016/j.clgc.2017.12.013. Epub 2018 Jan 4.

[Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.](#)

Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M.

J Urol. 2018 Jun;199(6):1446-1451. doi: 10.1016/j.juro.2017.12.057. Epub 2018 Jan 4.

[Pre-operative and post-operative estimated glomerular filtration rate in Japanese patients with urological malignancies.](#)

Niwa N, Yoshida T, Mizuno R, Kikuchi E, Miyajima A, Hayashi M, Oya M.

Clin Exp Nephrol. 2018 Oct;22(5):1205-1212. doi: 10.1007/s10157-017-1509-3. Epub 2017 Nov 27.

[Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guérin therapy.](#)

Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M.

Urol Oncol. 2018 Feb;36(2):77.e15-77.e21. doi: 10.1016/j.urolonc.2017.10.005. Epub 2017 Oct 31.

2017 年

[Factors influencing the operating time for single-port laparoscopic radical nephrectomy: focus on the anatomy and distribution of the renal artery and vein.](#)

Matsumoto K, Miyajima A, Fukumoto K, Komatsuda A, **Niwa N**, Hattori S, Takeda T, Kikuchi E, Asanuma H, Oya M.

Jpn J Clin Oncol. 2017 Oct 1;47(10):976-980. doi: 10.1093/jjco/hyx105.

[Renal hemorrhage caused by acquired inhibitors to coagulation factors VIII and V in a hemodialysis patient.](#)

Niwa N, Yoshida T, Mizuno R, Oya M, Hayashi M.

CEN Case Rep. 2016 Nov;5(2):223-226. doi: 10.1007/s13730-016-0229-y. Epub 2016 Jul 25.

[Simple and practical nomograms for predicting the stone-free rate after shock wave lithotripsy in patients with a solitary upper ureteral stone.](#)

Niwa N, Matsumoto K, Miyahara M, Omura M, Kobayashi H, Kikuchi E, Miyajima A, Miyata K, Oya M.

World J Urol. 2017 Sep;35(9):1455-1461. doi: 10.1007/s00345-017-2014-8. Epub 2017 Feb 20.

[Influence of physician years on urological journal publication productivity among Japanese urologists.](#)

Niwa N, Kikuchi E, Matsumoto K, Miyajima A, Oya M.

Springerplus. 2016 Nov 29;5(1):2040. eCollection 2016.

[Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation.](#)

Tanaka N, Kosaka T, Miyazaki Y, Mikami S, **Niwa N**, Otsuka Y, Minamishima YA, Mizuno R, Kikuchi E, Miyajima A, Sabe H, Okada Y, Uhlén P, Suematsu M, Oya M.

JCI Insight. 2016 Nov 3;1(18):e83654. doi: 10.1172/jci.insight.83654.

[Ureteral Stone in the Distal Blind-ending Branch of a Bifid Ureter.](#)

Niwa N, Ohigashi T, Bessho H, Arakawa T.

Urology. 2017 Jan;99:e23-e24. doi: 10.1016/j.urology.2016.10.003. Epub 2016 Oct 17.

[Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen.](#)

Matsumoto K, Komatsuda A, Yanai Y, **Niwa N**, Kosaka T, Mizuno R, Kikuchi E, Miyajima A, Oya M.

J Urol. 2017 Mar;197(3 Pt 1):655-661. doi: 10.1016/j.juro.2016.08.098. Epub 2016 Aug 30.

[Are the Formulas Used to Estimate Renal Function Adequate for Patients Treated With Cisplatin-Based Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Carcinoma?](#)

Niwa N, Kikuchi E, Masashi M, Tanaka N, Nishiyama T, Miyajima A, Saito S, Oya M.

Clin Genitourin Cancer. 2016 Oct;14(5):e501-e507. doi: 10.1016/j.clgc.2016.04.018. Epub 2016 May 2.

[Idiopathic hemocele in a patient receiving peritoneal dialysis.](#)

Niwa N, Yoshida T, Mizuno R.

Clin Exp Nephrol. 2017 Apr;21(2):350-351. doi: 10.1007/s10157-016-1279-3. Epub 2016 May 13. No abstract available.

2016 年

[Placebo-Induced Severe Diarrhea in a Patient With Metastatic Castration-Resistant Prostate Cancer Participating in a Double-Blind, Randomized, Phase III International Trial.](#)

Niwa N, Kosaka T, Oya M.

Clin Genitourin Cancer. 2016 Apr;14(2):e219-20. doi: 10.1016/j.clgc.2015.12.027. Epub 2015 Dec 24. No abstract available.

[Syndrome of inappropriate antidiuretic hormone secretion in a patient with castration-resistant prostate cancer treated with enzalutamide.](#)

Yanai Y, Matsumoto K, **Niwa N**, Kosaka T, Kikuchi E, Miyajima A, Ito H, Oya M.

Acta Oncol. 2016;55(3):399-400. doi: 10.3109/0284186X.2015.1054953. Epub 2015 Jun 16. No abstract available.

2015 年

[Schmorl Nodes Mimicking Osteolytic Bone Metastases.](#)

Niwa N, Nishiyama T, Ozu C, Yagi Y, Saito S.

Urology. 2015 Jul;86(1):e1-2. doi: 10.1016/j.urology.2015.03.028. Epub 2015 Jun 3.

[Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: A matched-pair analysis.](#)

Niwa N, Matsumoto K, Hayakawa N, Ito Y, Maeda T, Akatsuka S, Masuda T, Nakamura S, Tanaka N.

Urol Oncol. 2015 Sep;33(9):386.e15-21. doi: 10.1016/j.urolonc.2015.04.018. Epub 2015 May 28.

[Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib.](#)

Niwa N, Nishiyama T, Ozu C, Yagi Y, Saito S.

Acta Oncol. 2015 Apr;54(4):561-2. doi: 10.3109/0284186X.2014.963887. Epub 2014 Oct 7. No abstract available.

PMID: